Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms
Mirabegron has been registered as the first strong and selective agonist of the β3 receptor. It is currently used for relief of symptoms of overactive bladder (OAB). That onerous illness involving urgency and detrusor overactivity, that may be accompanied by incontinence, affects approx. 16% of the...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , |
|---|---|
| Fformat: | Llyfr |
| Cyhoeddwyd: |
Kazimierz Wielki University,
2018-08-01T00:00:00Z.
|
| Pynciau: | |
| Mynediad Ar-lein: | Connect to this object online. |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
| Rhif Galw: |
A1234.567 |
|---|---|
| Copi 1 | Ar gael |